Ketamine as a novel treatment for major depressive disorder and bipolar depression: A systematic review and quantitative meta-analysis

General Hospital Psychiatry

Volumn 37, Issue 2, 2015, Pages 178-184

  Lee, Ellen E ^a   Della Selva, Megan P ^a   Liu, Anson ^a   Himelhoch, Seth ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Ketamine; Meta analysis; Therapy

Indexed keywords

KETAMINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT;

ARTICLE; BIPOLAR DEPRESSION; DATA BASE; DISABILITY; DRUG EFFICACY; DRUG TOLERABILITY; EFFECT SIZE; HUMAN; INFORMATION RETRIEVAL; LOADING DRUG DOSE; MAJOR DEPRESSION; META ANALYSIS; MORBIDITY; MORTALITY; QUANTITATIVE ANALYSIS; RATING SCALE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR;

BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE;

EID: 84924916805     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2015.01.003     Document Type: Article

References (67)

1. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005, 62(6):617-627. 10.1001/archpsyc.62.6.617.
2. World Health Organization The global burden of disease: 2004 update 2008.
3. Collins P.Y., Patel V., Joestl S.S., et al. Grand challenges in global mental health. Nature 2011, 475(7354):27-30. 10.1038/475027a.
4. Bloom D.E., Cafiero E.T., Jané-Llopis E. The global economic burden of non-communicable diseases 2011, World Economic Forum, Geneva.
5. Chisholm D., Diehr P., Knapp M., et al. Depression status, medical comorbidity and resource costs. evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry 2003, 183:121-131.
6. Trivedi M.H., Fava M., Wisniewski S.R., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354(12):1243-1252. [doi: 354/12/1243 [pii]].
7. Fava M., Rush A.J., Alpert J.E., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008, 165(3):342-351. [doi]. 10.1176/appi.ajp.2007.06111868.
8. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11):1905-1917. [doi: 163/11/1905 [pii]].
9. Layer R.T., Popik P., Olds T., Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995, 52(3):621-627. [doi: 0091-3057(95)00155-P [pii]].
10. Meloni D., Gambarana C., De Montis M.G., Dal Pra P., Taddei I., Tagliamonte A. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993, 46(2):423-426.
11. Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993, 72(6):394-397.
12. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994, 263(1-2):1-7. [doi: 0014-2999(94)90516-9 [pii]].
13. Przegalinski E., Tatarczynska E., Deren-Wesolek A., Chojnacka-Wojcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997, 36(1):31-37. [doi: S0028390896001578 [pii]].
14. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185(1):1-10. doi: 0014-2999(90)90204-J [pii].
15. Sanacora G., Gueorguieva R., Epperson C.N., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61(7):705-713. [doi]. 10.1001/archpsyc.61.7.705.
16. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7(5):426-437. [doi]. 10.1038/nrd2462.
17. McCullumsmith R.E., Kristiansen L.V., Beneyto M., Scarr E., Dean B., Meador-Woodruff J.H. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007, 1127(1):108-118. [doi: S0006-8993(06)02719-3 [pii]].
18. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P. Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994, 269(1):95-102.
19. Boyer P.A., Skolnick P., Fossom L.H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci 1998, 10(3):219-233. [doi]. 10.1007/BF02761776.
20. Nowak G., Ordway G.A., Paul I.A. Alterations in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995, 675(1-2):157-164.
21. Holemans S., De Paermentier F., Horton R.W., Crompton M.R., Katona C.L., Maloteaux J.M. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 1993, 616(1-):138-143. [doi: 0006-8993(93)90202-X [pii]].
22. Aan Het Rot M., Zarate C.A., Charney D.S., Mathew S.J. Ketamine for depression: where do we go from here?. Biol Psychiatry 2012, 72(7):537-547. 10.1016/j.biopsych.2012.05.003.
23. DiazGranados N., Ibrahim L.A., Brutsche N.E., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010, 71(12):1605-1611. 10.4088/JCP.09m05327blu.
24. Zarate C.A., Singh J.B., Quiroz J.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163(1):153-155. [doi: 163/1/153 [pii]].
25. Diazgranados N., Ibrahim L., Brutsche N.E., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67(8):793-802. 10.1001/archgenpsychiatry.2010.90.
26. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864. 10.1001/archpsyc.63.8.856.
27. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4):351-354.
28. Murrough J.W., Iosifescu D.V., Chang L.C., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170(10):1134-1142. [doi]. 10.1176/appi.ajp.2013.13030392.
29. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013, 34(4):287-293.
30. Corazza O., Assi S., Schifano F. From "special K" to "special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 2013, 19(6):454-460. [doi]. 10.1111/cns.12063.
31. Schatzberg A.F. A word to the wise about ketamine. Am J Psychiatry 2014, 171(3):262-264. [doi]. 10.1176/appi.ajp.2014.13101434.
32. Katalinic N., Lai R., Somogyi A., Mitchell P.B., Glue P., Loo C.K. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 2013, 47(8):710-727. [doi]. 10.1177/0004867413486842.
33. McGirr A., Berlim M.T., Bond D.J., Fleck M.P., Yatham L.N., Lam R.W. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2014, 1-12. [doi: S0033291714001603 [pii]].
34. Caddy C., Giaroli G., White T.P., Shergill S.S., Tracy D.K. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014, 4(2):75-99. [doi]. 10.1177/2045125313507739.
35. Fond G., Loundou A., Rabu C., et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014, 231(18):3663-3676. [doi]. 10.1007/s00213-014-3664-5.
36. Walter M., Li S., Demenescu L.R. Multistage drug effects of ketamine in the treatment of major depression. Eur Arch Psychiatry Clin Neurosci 2014, 264(Suppl. 1):S55-S65. [doi]. 10.1007/s00406-014-0535-3.
37. Ghasemi M., Kazemi M.H., Yoosefi A., et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014, 215(2):355-361. [doi]. 10.1016/j.psychres.2013.12.008.
38. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002, 95(1):114-118. [table of contents].
39. Valentine G.W., Mason G.F., Gomez R., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011, 191(2):122-127. [doi]. 10.1016/j.pscychresns.2010.10.009.
40. Lapidus K.A., Levitch C.F., Perez A.M., et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014, 76(12):970-976. [doi]. 10.1016/j.biopsych.2014.03.026.
41. aan het Rot M., Collins K.A., Murrough J.W., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67(2):139-145. [doi]. 10.1016/j.biopsych.2009.08.038.
42. Paslakis G., Gilles M., Meyer-Lindenberg A., Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010, 43(1):33-35. [doi]. 10.1055/s-0029-1237375.
43. Ibrahim L., Diazgranados N., Franco-Chaves J., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37(6):1526-1533. 10.1038/npp.2011.338; 10.1038/npp.2011.338.
44. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010, 13(1):71-82. 10.1017/S1461145709000169.
45. Moukaddam N.J., Hirschfeld R.M. Intravenous antidepressants: a review. Depress Anxiety 2004, 19(1):1-9. [doi]. 10.1002/da.10135.
46. Dalgarno P.J., Shewan D. Illicit use of ketamine in scotland. J Psychoactive Drugs 1996, 28(2):191-199. [doi]. 10.1080/02791072.1996.10524391.
47. McCambridge J., Winstock A., Hunt N., Mitcheson L. 5-year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 2007, 13(1):57-64. [doi: 000095816 [pii]].
48. Shahani R., Streutker C., Dickson B., Stewart R.J. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007, 69(5):810-812. [doi: S0090-4295(07)00101-X [pii]].
49. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66(5):522-526. [doi]. 10.1016/j.biopsych.2009.04.029.
50. Zarate C.A., Brutsche N., Laje G., et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 2012, 72(4):331-338. [doi]. 10.1016/j.biopsych.2012.03.004.
51. Fond G., Boyer L. Ketamine's effectiveness in unipolar versus bipolar depression. Psychopharmacology (Berl) 2014, 231(22):4417-4418. [doi]. 10.1007/s00213-014-3773-1.
52. Salvadore G., van der Veen J.W., Zhang Y., et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 2012, 15(8):1063-1072. [doi]. 10.1017/S1461145711001593.
53. Salvadore G., Cornwell B.R., Sambataro F., et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35(7):1415-1422. [doi]. 10.1038/npp.2010.24.
54. Salvadore G., Cornwell B.R., Colon-Rosario V., et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009, 65(4):289-295. [doi]. 10.1016/j.biopsych.2008.08.014.
55. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol Psychiatry 2009, 65(2):181-184. 10.1016/j.biopsych.2008.09.029.
56. Dietrich D.E., Bode L., Spannhuth C.W., et al. Amantadine in depressive patients with borna disease virus (BDV) infection: an open trial. Bipolar Disord 2000, 2(1):65-70.
57. Ferszt R., Severus E., Bode L., et al. Activated borna disease virus in affective disorders. Pharmacopsychiatry 1999, 32(3):93-98. [doi]. 10.1055/s-2007-979201.
58. Ferszt R., Kuhl K.P., Bode L., et al. Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with borna disease virus infection. Pharmacopsychiatry 1999, 32(4):142-147. [doi]. 10.1055/s-2007-979220.
59. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28(6):631-637. [doi]. 10.1097/JCP.0b013e31818a6cea.
60. Ibrahim L., Diaz Granados N., Jolkovsky L., et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012, 32(4):551-557. [doi]. 10.1097/JCP.0b013e31825d70d6.
61. Murrough J.W., Charney D.S. Is there anything really novel on the antidepressant horizon?. Curr Psychiatry Reps 2012, 14(6):643-649. [doi]. 10.1007/s11920-012-0321-8.
62. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351-4.
63. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802. http://dx.doi.org/10.1001/archgenpsychiatry.2010.90; 10.1001/archgenpsychiatry.2010.90.
64. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 2013;170(10):1134-42. http://dx.doi.org/10.1176/appi.ajp.2013.13030392 [doi].
65. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013;34(4):287-93.
66. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of anN-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64. http://dx.doi.org/10.1001/archpsyc.63.8.856.
67. Zarate Jr CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939-46. http://dx.doi.org/10.1016/j.biopsych.2011.12.010; 10.1016/j.biopsych.2011.12.010.